{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yuan Y"],"funding":["Sun Yat-Sen University Clinical Research 5010 Programme","National Natural Science Foundation of China"],"pagination":["1337-1349"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11570767"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["44(11)"],"pubmed_abstract":["<h4>Background</h4>The widely accepted view that portal hypertension (PHT) is a contraindication to hepatectomy for patients with hepatocellular carcinoma (HCC) is being increasingly challenged. The long-term survival outcomes and safety of partial hepatectomy versus interventional treatment using ablation with or without pre-ablation transarterial chemoembolization (TACE) in patients with HBV-related HCC within the Milan criteria and with clinically significant PHT were compared in this study.<h4>Methods</h4>This open-label randomized clinical trial was conducted on consecutive patients with clinically PHT and hepatitis B virus (HBV)-related HCC with tumors which were within the Milan criteria. These patients were randomized 1:1 to receive either partial hepatectomy or interventional trea"],"journal":["Cancer communications (London, England)"],"pubmed_title":["Partial hepatectomy versus interventional treatment in patients with hepatitis B virus-related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinical trial."],"pmcid":["PMC11570767"],"funding_grant_id":["No. 82272887","2012010"],"pubmed_authors":["Peng H","Qiu J","Zheng Y","He W","Wang C","Zou R","Li B","Chen B","Lau WY","Yuan Y"],"additional_accession":[]},"is_claimable":false,"name":"Partial hepatectomy versus interventional treatment in patients with hepatitis B virus-related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinical trial.","description":"<h4>Background</h4>The widely accepted view that portal hypertension (PHT) is a contraindication to hepatectomy for patients with hepatocellular carcinoma (HCC) is being increasingly challenged. The long-term survival outcomes and safety of partial hepatectomy versus interventional treatment using ablation with or without pre-ablation transarterial chemoembolization (TACE) in patients with HBV-related HCC within the Milan criteria and with clinically significant PHT were compared in this study.<h4>Methods</h4>This open-label randomized clinical trial was conducted on consecutive patients with clinically PHT and hepatitis B virus (HBV)-related HCC with tumors which were within the Milan criteria. These patients were randomized 1:1 to receive either partial hepatectomy or interventional trea","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-07-15T04:58:55.256Z","creation":"2025-04-21T21:45:48.286Z"},"accession":"S-EPMC11570767","cross_references":{"pubmed":["39322951"],"doi":["10.1002/cac2.12614"]}}